Scarica l'app Stockscreener
2.58
4.09%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.69
Aprire:
$2.67
Volume 24 ore:
1.18M
Relative Volume:
0.49
Capitalizzazione di mercato:
$395.93M
Reddito:
$38.69M
Utile/perdita netta:
$-108.95M
Rapporto P/E:
-2.1104
EPS:
-1.2225
Flusso di cassa netto:
$-141.09M
1 W Prestazione:
-0.77%
1M Prestazione:
-20.37%
6M Prestazione:
+29.65%
1 anno Prestazione:
+2.79%
Intervallo 1D:
$2.53
$2.7025
Intervallo di 1 settimana:
$2.52
$2.725
Portata 52W:
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.58 | 411.28M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
EDIT|Editas Medicine Inc|Price:2.680|Chg%:+0.080 - TradingKey
Editas Medicine Inc (EDIT) Cash Flow - TradingKey
Editas Medicine Inc (EDIT) Income Statement - TradingKey
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine Inc (EDIT) Balance Sheet - TradingKey
Editas Medicine, Inc. Revenue Breakdown – NASDAQ:EDIT - TradingView
Editas Medicine Inc (EDIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Editas Medicine Slips 2.34% as Gene Editing Stock Tests Key Support at $2.57Fear Greed Extreme - dars.gov.et
Form 144 Editas Medicine For: 22 July By Investing.com - Investing.com Nigeria
Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends - Ad-hoc-news.de
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting - Stock Titan
Editas Medicine (EDIT) 10K Form and Latest SEC Filings 2026 - MarketBeat
Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrows - Ad-hoc-news.de
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Lyora Therapeutics Launches With Seed Funding to Advance Genetic Eye Disease Therapies - citybiz
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases - GlobeNewswire Inc.
Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen - Endpoints News
Editas Medicine (EDIT) Slips 1.21%, Tests Support Near $3.10 Amid Gene-Editing Sector PressurePullback Trade - dars.gov.et
What pharma leaders wish they knew on day 1 - Pharma Voice
Editas Medicine Slips Slightly, Holds Above Key Support LevelHigh Yield Stocks - DonanımHaber
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com
Editas Medicine stock holds the line as pipeline work continues. - Ad Hoc News
Editas Medicine Surges 11% on Strong Volume, Testing Key Resistance at $3.83Long Short Pair - dars.gov.et
EDIT's Q1 loss narrower than expected, pipeline in focus - MSN
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to sales forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Price to earnings forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Enterprise value to revenue forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
EDIT Q1 2026 Earnings: Narrowing Losses Amid Pipeline ProgressMid-Term Outlook - dars.gov.et
Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT) - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK) - TradingView
EDIT Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine, Inc. Actuals & Estimates (FWB:8EM) - TradingView
Editas Medicine Inc (EDIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Editas Medicine, Inc. Actuals & Estimates (BOATS:EDIT) - TradingView
8EM Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew - Moomoo
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
Editas Medicine Inc (EDIT) Institutional Confidence - TradingKey
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Editas Medicine Inc Azioni (EDIT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Jun 03 '26 |
Sale |
2.70 |
464 |
1,253 |
14,970 |
| O'Neill Gilmore Neil | CEO |
Jun 03 '26 |
Sale |
2.70 |
15,380 |
41,543 |
248,313 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '26 |
Sale |
2.70 |
731 |
1,975 |
67,297 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):